Background And Objectives: There is limited information on the transient or persistent no reflow phenomenon in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI).

Subjects And Methods: The study analyzed 4329 patients with AMI from a Korean multicenter registry who underwent PCI using coronary stents (2668 ST-elevation and 1661 non-ST-elevation myocardial infarction [MI] patients): 4071 patients without any no reflow, 213 with transient no reflow (no reflow with final thrombolysis in myocardial infarction [TIMI] flow grade 3), and 45 with persistent no reflow (no reflow with final TIMI flow grade≤2). The primary endpoint was all-cause mortality during 3-year follow-up. We also analyzed the incidence of cardiac mortality, non-fatal MI, re-hospitalization due to heart failure, target vessel revascularization, and stent thrombosis.

Results: The persistent no reflow group was associated with higher all-cause mortality (hazard ratio [HR] 1.98, 95% confidence interval [CI] 1.08-3.65, p=0.028) and cardiac mortality (HR 3.28, 95% CI 1.54-6.95, p=0.002) compared with the normal reflow group. Transient no reflow increased all-cause mortality only when compared with normal reflow group (HR 1.58, 95% CI 1.11-2.24, p=0.010). When comparing transient and persistent no reflow, persistent no reflow was associated with increased all-cause mortality (46.7 vs. 24.4%, log rank p=0.033).

Conclusion: The persistent no reflow phenomenon was associated with a poor in-hospital outcome and increased long-term mortality mainly driven by increased cardiac mortality compared to the transient no reflow phenomenon or normal reflow.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4965427PMC
http://dx.doi.org/10.4070/kcj.2016.46.4.490DOI Listing

Publication Analysis

Top Keywords

persistent reflow
28
reflow
16
myocardial infarction
16
all-cause mortality
16
transient persistent
12
reflow phenomenon
12
transient reflow
12
cardiac mortality
12
reflow group
12
normal reflow
12

Similar Publications

Recanalization Does Not Always Equate to Reperfusion: No-Reflow Phenomenon After Successful Thrombectomy.

Stroke

January 2025

Department of Neurosurgery, Graduate School of Biomedical and Health Sciences, Hiroshima University, Japan (N.H., T.H., M.K., H.K., D.I.).

Background: Thrombectomy for acute large vessel occlusion is a well-established treatment for stroke prevention. However, futile recanalization cases, where no-reflow occurs despite successful recanalization, have been reported. This study aimed to assess cerebral hemodynamics immediately after thrombectomy and their relationship with clinical outcomes.

View Article and Find Full Text PDF

Leaftronics: Natural lignocellulose scaffolds for sustainable electronics.

Sci Adv

November 2024

Dresden Integrated Center for Applied Physics and Photonic Materials (IAPP) and Institute for Applied Physics, Technische Universität Dresden, 01187 Dresden, Germany.

The global rise in electronic waste is alarming, driven by the persistent use of glass, epoxy, and plastic substrates owing to their cost, stability, flexibility, and transparency. This underscores the need for biodegradable alternatives with similar properties. This study shows that leaf-derived lignocellulose scaffolds can stabilize bio-sourced, solution-processed polymers by acting as natural sequestering media.

View Article and Find Full Text PDF

Background: Acute coronary syndrome (ACS) remains one of the leading causes of death worldwide. Smoking may also increase the risk of developing ACS. The most advantageous therapy is percutaneous coronary intervention.

View Article and Find Full Text PDF
Article Synopsis
  • The study aimed to assess the effectiveness of post-PCI sonothrombolysis in reducing no-reflow and infarct size in STEMI patients with ongoing ST elevation after treatment.
  • A total of 67 STEMI patients were randomly assigned to either the sonothrombolysis group or a control group, but the results showed no significant differences in key outcomes such as ST elevation, infarct size, or myocardial function after treatment.
  • Overall, the study concluded that post-PCI sonothrombolysis did not provide a measurable benefit compared to standard care in STEMI patients with persistent ST elevation.
View Article and Find Full Text PDF

While the efficacy of GpIIb-IIIa-inhibitors during primary PCI (pPCI) for ST-elevated myocardial infarction (STEMI) has previously been demonstrated, its ongoing role and safety in combination with newer P2Y12-inhibitors is unclear. We therefore sought to compare outcomes between two centers with divergent approaches to the use of GpIIbIIIa antagonists in pPCI. We performed a retrospective chart review of all-comer STEMI patients treated with pPCI at two high-volume Montreal academic tertiary care centers.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!